Safety, pharmacokinetics and pharmacodynamics of the anti‐hepcidin Spiegelmer lexaptepid pegol in healthy subjects
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Anaemia of chronic disease is characterized by impaired erythropoiesis due to functional iron deficiency, often caused by excessive hepcidin. Lexaptepid pegol, a pegylated structured l‐oligoribonucleotide, binds and inactivates hepcidin. Experimental Approach: We conducted a placebo‐controlled study on the safety, pharmacokinetics and pharmacodynamics of lexaptepid after single and repeated i.v. and s.c. administration to 64 healthy subjects at doses from 0.3 to 4.8 mg·kg−1. Key Results: After treatment with lexaptepid, serum iron concentration and transferrin increased dose‐dependently. Iron increased from approximately 20 μmol·L−1 at baseline by 67% at 8 h after i.v. infusion of 1.2 mg·kg−1 lexaptepid. The pharmacokinetics showed dose‐proportional increases in peak plasma concentrations and moderately over‐proportional increases in systemic exposure. Lexaptepid had no effect on hepcidin production or anti‐drug antibodies. Treatment with lexaptepid was generally safe and well tolerated, with mild and transient transaminase increases at doses ≥2.4 mg·kg−1 and with local injection site reactions after s.c. but not after i.v. administration. Conclusions and Implications: Lexaptepid pegol inhibited hepcidin and dose‐dependently raised serum iron and transferrin saturation. The compound is being further developed to treat anaemia of chronic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 1×
“It inhibits the release of intracellular iron from duodenal enterocytes, hepatocytes and reticuloendothelial cells by binding to the membrane iron exporter ferroportin, which leads to its internalization and inactivation (Nemeth et al., 2004; Nemeth and Ganz, 2006).”
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Hepcidin, a urinary antimicrobial peptide synthesized in the liver
Park, C. H., Valore, E. V., Waring, A. J., & Ganz, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008922200 · Cited by 2,168 · cited 2×
“Hepcidin, a 25-amino-acid peptide produced by the liver (Krause et al., 2000; Park et al., 2001; Pigeon et al., 2001), has emerged as the key regulator of systemic iron homeostasis (Ganz, 2003; Roy et al., 2007).”
Pigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., & Loréal, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008923200 · Cited by 1,697 · cited 2×
“Hepcidin, a 25-amino-acid peptide produced by the liver (Krause et al., 2000; Park et al., 2001; Pigeon et al., 2001), has emerged as the key regulator of systemic iron homeostasis (Ganz, 2003; Roy et al., 2007).”
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
Ganz, T. (2003) · Blood · doi:10.1182/blood-2003-03-0672 · Cited by 1,544 · cited 2×
“, 2001), has emerged as the key regulator of systemic iron homeostasis (Ganz, 2003; Roy et al., 2007).”
LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity
Krause, A., Neitz, S., Mägert, H.-J., Schulz, A., Forssmann, W.-G., Schulz-Knappe, P., & Adermann, K. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01920-7 · Cited by 1,324 · cited 2×
“Hepcidin, a 25-amino-acid peptide produced by the liver (Krause et al., 2000; Park et al., 2001; Pigeon et al., 2001), has emerged as the key regulator of systemic iron homeostasis (Ganz, 2003; Roy et al., 2007).”
Identification of erythroferrone as an erythroid regulator of iron metabolism
Kautz, L., Jung, G., Valore, E. V., Rivella, S., Nemeth, E., & Ganz, T. (2014) · Nature Genetics · doi:10.1038/ng.2996 · Cited by 1,127 · cited 1×
“Hepcidin expression is inhibited by erythropoietic activity through certain factors such as growth differentiation factor 15 (Tanno et al., 2007), twisted gastrulation protein homologue 1 (Tanno et al., 2009) and erythroferrone (Kautz et al., 2014).”
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin
Tanno, T., Bhanu, N. V., Oneal, P. A., Goh, S.-H., Staker, P., Lee, Y. T., Moroney, J. W., Reed, C. H., Luban, N. L., Wang, R.-H., et al. (2007) · Nature Medicine · doi:10.1038/nm1629 · Cited by 854 · cited 2×
“Hepcidin expression is inhibited by erythropoietic activity through certain factors such as growth differentiation factor 15 (Tanno et al., 2007), twisted gastrulation protein homologue 1 (Tanno et al.”
Regulation of Iron Metabolism by Hepcidin
Nemeth, E., & Ganz, T. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111303 · Cited by 756 · cited 1×
“It inhibits the release of intracellular iron from duodenal enterocytes, hepatocytes and reticuloendothelial cells by binding to the membrane iron exporter ferroportin, which leads to its internalization and inactivation (Nemeth et al., 2004; Nemeth and Ganz, 2006).”
Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway
Cohen, L. A., Gutierrez, L., Weiss, A., Leichtmann-Bardoogo, Y., Zhang, D.-L., Crooks, D. R., Sougrat, R., Morgenstern, A., Galy, B., Hentze, M. W., et al. (2010) · Blood · doi:10.1182/blood-2009-11-253815 · Cited by 452 · cited 1×
“Under conditions of elevated iron stores in the reticuloendothelial system (RES), the inhibition of hepcidin should release intracellular iron from the RES and thus, over time, should decrease serum ferritin concentrations (Cohen et al., 2010), as observed in a study in cancer patients with ACD and high baseline ferri…”
Tanno, T., Porayette, P., Sripichai, O., Noh, S.-J., Byrnes, C., Bhupatiraju, A., Lee, Y. T., Goodnough, J. B., Harandi, O., Ganz, T., et al. (2009) · Blood · doi:10.1182/blood-2008-12-195503 · Cited by 352
Song, S.-N. J., Tomosugi, N., Kawabata, H., Ishikawa, T., Nishikawa, T., & Yoshizaki, K. (2010) · Blood · doi:10.1182/blood-2010-03-271791 · Cited by 228 · cited 4×
“TARGETS Transporters Ferroportin, SLC40A1 LIGANDS Hepcidin IL-12 IL-6 Tocilizumab These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al.,…”
InfluentialHepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation
Roy, C. N., Mak, H. H., Akpan, I., Losyev, G., Zurakowski, D., & Andrews, N. C. (2007) · Blood · doi:10.1182/blood-2006-10-051755 · Cited by 178
Schwoebel, F., van Eijk, L. T., Zboralski, D., Sell, S., Buchner, K., Maasch, C., Purschke, W. G., Humphrey, M., Zöllner, S., Eulberg, D., et al. (2013) · Blood · doi:10.1182/blood-2012-09-456756 · Cited by 158
Self-citationvan Eijk, L. T., John, A. S. E., Schwoebel, F., Summo, L., Vauléon, S., Zöllner, S., Laarakkers, C. M., Kox, M., van der Hoeven, J. G., Swinkels, D. W., et al. (2014) · Blood · doi:10.1182/blood-2014-03-559484 · Cited by 110
Self-citationCellular Catabolism of the Iron-Regulatory Peptide Hormone Hepcidin
Preza, G. C., Pinon, R., Ganz, T., & Nemeth, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058934 · Cited by 56
Witcher, D. R., Leung, D., Hill, K. A., De Rosa, D. C., Xu, J., Manetta, J., Wroblewski, V. J., & Benschop, R. J. (2013) · Blood · doi:10.1182/blood.v122.21.3433.3433 · Cited by 29
Moebius, U., Feuerer, W., Fenzl, E., van Swelm, R., Swinkels, D. W., & Hohlbaum, A. (2015) · Blood · doi:10.1182/blood.v126.23.536.536 · Cited by 14
Self-citationPhase 1 study of a hepcidin antagonist, LY2787106, in cancer-associated anemia
Vadhan-Raj, S., Abonour, R., Goldman, J. W., Smith, D. A., Slapak, C. A., Tiu, R. V., Wang, X., Callies, S., Cox, J., Tuttle, J. L., et al. (2015) · Blood · doi:10.1182/blood.v126.23.537.537 · Cited by 6
Research works printed but not linked: 12
- 10.1111/bph.13355 · DOI · Paper page
- 10.3324/haematol.2015.133983 · DOI
- 10.3324/haematol.2013.084624 · DOI · Paper page
- 10.1158/1538-7445.AM2014-3847 · DOI
- 10.1007/s00467-006-0405-y · DOI
- 10.1373/clinchem.2010.149187 · DOI · Paper page
- 10.1093/ndt/17.suppl_11.39 · DOI · Paper page
- 10.1093/nar/gkt1143 · DOI · Paper page
- 10.1016/j.amjmed.2012.01.015 · DOI · Paper page
- 10.1371/journal.pone.0002706 · DOI · Paper page
- 10.1016/j.bbagen.2010.03.011 · DOI · Paper page
- 10.1208/s12248-010-9222-0 · DOI
Cited by
Iron metabolism and iron disorders revisited in the hepcidin era
Camaschella, C., Nai, A., & Silvestri, L. (2020) · Haematologica · doi:10.3324/haematol.2019.232124 · Cited by 734
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01606-1 · Cited by 608
Ganz, T. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1804281 · Cited by 589
Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications
Ni, S., Zhuo, Z., Pan, Y., Yu, Y., Li, F., Liu, J., Wang, L., Wu, X., Li, D., Wan, Y., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c05750 · Cited by 589
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A.-M., Choi, Y. H., & Tu, M.-J. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 395
Metadata
- Authors
- Boyce, M., Warrington, S., Cortezi, B., Zöllner, S., Vauléon, S., Swinkels, D. W., Summo, L., Schwoebel, F., & Riecke, K.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2016-04-08
- Volume
- 173
- Issue
- 10
- Pages
- 1580-1588
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2237988842
- Cited by
- 82
- References
- 19
- FWCI
- 7.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.